Evaluate Vantage
PD(L)anner - March 2022
Evaluate Vantage®
REPORT DOWNLOAD
The Evaluate Vantage PD(L)anner – March 2022 provides news, insights and analysis on the PD-(L)1 antibody landscape. Among other issues, we focus on potential pricing changes, provide an update on what’s happening in China and other markets, and share our views on the results of recent studies.
To access your complimentary copy of this special report, please fill in this form.
.
REPORT HIGHLIGHTS
Pricing competition:
So far there has been almost no pricing competition in the US, despite a number of drugs being available on the market. This could soon start to shift, though, as potential new market entrants emerge.
So far there has been almost no pricing competition in the US, despite a number of drugs being available on the market. This could soon start to shift, though, as potential new market entrants emerge.
China’s impact:
An attempt to secure FDA approval based on trial data entirely from China looks likely to end in failure. Does this preclude others from taking a serious step towards bigger changes in the market?
An attempt to secure FDA approval based on trial data entirely from China looks likely to end in failure. Does this preclude others from taking a serious step towards bigger changes in the market?
Recent studies:
Which studies have read out positively since the last report – and which have not? We discuss the key takeaways.
Which studies have read out positively since the last report – and which have not? We discuss the key takeaways.
